Company Overview and News


Add TEVJF
to your dashboard

Headline News

Doctors Are Cutting Off Opioids, Leaving Millions of Patients Facing Pain and Withdrawal - Bloomberg

2h bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (129-0)

Teva Pharmaceutical Industries Limited 2017 Q3 - Results - Earnings Call Slides

15h seekingalpha
The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with their 2017 Q3 earnings call. (129-0)

A Look at Merck’s Cardiovascular Portfolio in 3Q17

19h marketrealist
In 3Q17, Merck’s (MRK) Zetia generated revenue of ~$320 million, which reflected a ~52% fall YoY (year-over-year) and a ~13% fall QoQ (quarter-over-quarter). Vytorin reported revenue of $142 million, which reflected a ~48% fall YoY and a 22% fall QoQ. (130-0)

10 Blue-Chip Stocks That Could Wreck Your Retirement | InvestorPlace

2017-11-17 investorplace
There’s an old saw on Wall Street that you don’t make a profit until you sell. Paper profits are meaningless. (300-0)

What We Can Learn From Teva's Q3 Report

2017-11-17 seekingalpha
Teva has to sell some of its businesses to (1) raise cash for debt repayment and (2) comply with FTC and EC regulations. (134-1)

Why AstraZeneca’s Revenues Rose in 3Q17

2017-11-16 marketrealist
As we saw in the first part of this series, AstraZeneca (AZN) released its 3Q17 earnings on November 9, 2017. It reported 3Q17 revenues of $6.2 billion, a rise of 10% at constant exchange rates compared to $5.7 billion in 3Q16. (129-0)

Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets 2 FDA Approvals, GW Pharmaceuticals' Price Target Lowered

2017-11-15 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (1487-9)

WVE / WAVE Life Sciences Ltd. - Stock Institutional Ownership and Shareholders - Fintel.io

2017-11-15 fintel.io
WAVE Life Sciences Ltd. (NASDAQ:WVE) has 58 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 22,300,200 shares. Largest shareholders include Ra Capital Management, Llc, Redmile Group, LLC, Price T Rowe Associates Inc /md/, FMR LLC / Fidelity Management & Research, and Teva Pharmaceutical Industries Ltd. (136-0)

Your Daily Pharma Scoop: Portola Ahead Of Catalysts, AstraZeneca Gets Two FDA Approvals, GW Pharmaceuticals' Price Target Lowered

2017-11-15 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (1487-2)

Despite Valeant Improvement, VRX Stock Price Is Still Too High

2017-11-15 investorplace
Give credit where credit is due. New CEO Joe Papa has done a nice job in his efforts to turn around Valeant Pharmaceuticals Intl Inc (NYSE:VRX). So far, it hasn’t done much for the VRX stock price, which is basically flat so far in 2017. But flat performance in this market actually isn’t that bad. (324-0)

AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA

2017-11-15 zacks
AstraZeneca, plc (AZN - Free Report) announced that the FDA has granted approval to its asthma disease candidate, benralizumab. Benralizumab, approved as an add-on maintenance treatment for severe eosinophilic asthma in patients aged 12 years and older, will be marketed by the trade name of Fasenra. (237-0)

Healthcare Dogfight: GlaxoSmithKline Regains Top By Gains In November As O&M & Patterson Close-In

2017-11-14 seekingalpha
GSK regained top dog by net gains, while TEVJF led again by yield as calculated 11/13/17. (174-0)

Orexigen (OREX) Q3 Loss Narrower Than Expected, Stock Up

2017-11-14 zacks
Orexigen Therapeutics, Inc (OREX - Free Report) reported net loss of $1.35 per share for the third quarter of 2017, which was narrower than the Zacks Consensus Estimate of a loss of $2.13. The company had reported earnings of $1.12 in the year-ago period mainly due to a non-cash settlement gain of $80.2 million, which was recorded as deferred revenues previously. (163-0)

Deals of the day-Mergers and acquisitions

2017-11-14 reuters
Nov 14 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1100 GMT on Tuesday: (259-3)

Top Analyst Upgrades and Downgrades: Best Buy, Equifax, Gilead, MongoDB, NVIDIA, Rio Tinto, Teva, UPS and Many More

2017-11-13 247wallst
Stocks were indicated to open lower on Monday, with all major U.S. equity indexes down about 0.3% on average. What investors still need to consider is that the stock indexes have bumped up against all-time highs, and the trend that has dominated is that investors have bought every major sell-off for more than five years now. Investors are also looking for new investing and trading ideas to generate gains and income ahead. (385-1)

CUSIP: M8769Q136